Early-onset neonatal sepsis

Area of Science:

• Neonatal Medicine
• Infectious Diseases
• Microbiology

Background:

• Early-onset sepsis (EOS) is a critical neonatal health issue, especially for preterm infants.
• Group B Streptococcus (GBS) is a primary cause, but Escherichia coli leads to higher mortality.
• Maternal antimicrobial prophylaxis reduced GBS but increased Gram-negative infections in very-low-birth-weight infants.

Purpose of the Study:

• To review the current understanding of neonatal sepsis, including etiologic agents and diagnostic approaches.
• To highlight challenges in diagnosis and treatment of neonatal infections.
• To discuss emerging research, particularly vaccine development for GBS.

Main Methods:

• Review of clinical presentation and diagnostic markers for neonatal sepsis.
• Analysis of current antimicrobial prophylaxis strategies and their impact.
• Examination of molecular methods and biomarkers for sepsis detection.
• Consideration of viral pathogens in differential diagnosis.

Main Results:

• Diagnosis relies on clinical signs, nonspecific markers (CRP, procalcitonin), blood cultures, and molecular methods (PCR).
• Biomarkers like cytokines (IL-6, IL-8, IFN-γ, TNF-α) and cell surface antigens (sICAM, CD64) are under investigation.
• Viral infections (enteroviruses, parechoviruses, HSV) are important differentials.
• Empirical treatment varies based on resistance patterns, commonly ampicillin with gentamicin or cefotaxime.

Conclusions:

• Neonatal sepsis diagnosis requires a multifaceted approach combining clinical, laboratory, and molecular data.
• Antimicrobial resistance patterns influence empirical treatment choices.
• Vaccine development against GBS is a key area of ongoing research to prevent neonatal infections.